Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 72 Next >>

Filter Applied: myasthenia gravis (Click to remove)

Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972

Cytomegalovirus Infection and Cryptococcal Infection in Patient with Immunosuppression with Myasthenia Gravis
NEJM 395:804-815, Ankomah,P.O.,et al, 2026

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis, The PREVAIL Phase 3 Randomized Clinical Trial
JAMA Neurol 83:841-850, Gwathmey,K.G.,et al, 2026

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025

Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Neurologic Manifestations of Hyperthyroidism and Graves Disease
www.UptoDate.com, Oct 28, Rubin,D.I., 2024

A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021

Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020

Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018

Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018

Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018

Myasthenia Gravis Exacerbation after Discontinuing Mycophenolate
Neurol 86:1159-1163, Oskarsson, B.,et al, 2016

Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation
JAMA Neurol 73:652-658,624, Bryant, A.,et al, 2016

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016

Myasthenia Gravis after Botulinum Toxin Type A Injection
Turk J Neurol 22:143-144, Tekce, H.D.,et al, 2016

Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016

Differential Diagnosis of Finger Drop
Neurologist 19:128-131, Varatharaj, A.,et al, 2015

Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014

Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014

Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012

The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011

Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011

Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010

Tempo of Disease. In Merritts Neurology. Signs and symptoms in neurologic diagnosis: Approach to the patient
, Rowland, L.P.,et al, 2009

A Case with Myasthenia Gravis, Brain Stem Multiple Infarcts, Fracture of Vertebrai Th6 and discal hernia to the Th7/Th8
Radiol Oncol 43:3:170-174, KuKaj,V.,et al, 2009

An International, Phase III, Randomized Trial of Mycophenolate Mofetil in Myasthenia Gravis
Neurol 71:400-406, 390, Sanders,D.B.,et al., 2008

Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007

Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Arch Neurol 64:1790-1792,1794, Gilbert,M.E.,et al, 2007

Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006

Myasthenia gravis Exacerbation or Unmasking Associated With Telithromycin Treatment
Neurol 67:2256-2258, Perrot,S.,et al, 2006

Primary CNS Lymphoma in Myasthenic on Long-term Azathioprine
J NeuroOncol 74:91-92, Finelli,P.F., 2005

Primary CNS Lymphoma Complicating Treatment of Myasthenia Gravis with Mycophenolate Mofetil
Neurol 65:639-641, Vernino,S.,et al, 2005

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Statin-Associated Exacerbation of Myasthenia Gravis
Neurol 63:2188, Cartwright,M.S.,et al, 2004

Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003

Myasthenia Gravis
Neurol 61:1362-1366, Hoff,J.M.,et al, 2003

Steroid Treatment for Myasthenia Gravis
Muscle Nerve 25:115-121, Rivner,M.H., 2002

Antiphospholipid Syndrome and Multiple Ischemic Strokes in a Patient with Myasthenia Gravis
Kurume Med J 49:211-216, Kaji, M.,et al, 2002

Myasthenia Mimicking Vertobrobasilar Stroke
J Neurol 249:1512-1514, Libman,R.,et al, 2002

The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathol 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001

Retrospective Analysis of the Use of Cyclosporine in Myasthenia Gravis
Neurol 55:448-450, Ciafaloni,E. et al, 2000

Association of Primary Central Nervous System Lymphoma with Long-Term Azathioprine Therapy for Myasthenia Gravis?
Ann Neurol 47: 682-683, Herrlinger,U.,et al, 2000



Showing articles 0 to 50 of 72 Next >>